Fate Therapeutics, Inc.
Fate Therapeutics, Inc. (FATE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FATE · as of Sep 30, 2025
Ownership Breakdown
145
Institutional Holders
▲ 2 vs Q2
$101.61M
Total Inst. Value
▲ $12.63M vs Q2
116.56M
Shares Outstanding
freeFloat 87.39%
80.62M
13F Shares Held
▲ 938,531 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FATE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
REDMILE GROUP, LLC biological products, (no diagnostic substances) | 12.87M | 10.86% | 10.86% | $16.22B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 10.68M | 9.01% | 9.01% | $13.46B | Nov 12, 2025 | ▼ 129.8K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 8.80M | 7.42% | 7.42% | $11.09B | Nov 7, 2025 | ▲ 31.7K |
WILSHIRE ADVISORS LLC biological products, (no diagnostic substances) | 8.49M | 7.16% | 7.16% | $10.69B | Nov 14, 2025 | ▲ 8.49M |
JOHNSON & JOHNSON biological products, (no diagnostic substances) | 3.38M | 2.85% | 2.85% | $4.26B | Mar 18, 2026 | — held |
ACADIAN ASSET MANAGEMENT LLC biological products, (no diagnostic substances) | 2.71M | 2.29% | 2.29% | $3.41B | Nov 13, 2025 | ▲ 250.3K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.53M | 2.13% | 2.13% | $3.19B | Nov 12, 2025 | ▲ 101.0K |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 2.52M | 2.12% | 2.12% | $3.17B | Nov 14, 2025 | — held |
STATE STREET CORP biological products, (no diagnostic substances) | 2.42M | 2.04% | 2.04% | $3.05B | Nov 14, 2025 | ▲ 188.0K |
DIMENSIONAL FUND ADVISORS LP biological products, (no diagnostic substances) | 2.09M | 1.77% | 1.77% | $2.64B | Nov 12, 2025 | ▼ 342.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
24
Increased
+13.09M shares4
New Positions
first time holders14
Decreased
−8.68M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.41M
+13.09M / −8.68M
Net new holders
+14
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FATE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
11
Buy transactions
9
Sell transactions
1.22
Buy/Sell ratio
$14M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
TAHL CINDY See Remarks | May 20, 2026 | Sale | 25,590 | $1.88 | $48.1K | 628.2K | Form 4 ↗ |
Valamehr Bahram President and CEO | May 20, 2026 | Sale | 28,946 | $1.88 | $54.5K | 635.8K | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 266,280 | $5.84 | $1.56M | 502.8K | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 266,280 | $5.84 | $1.56M | 0 | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 8,977,624 | — | — | 12.88M | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 3,691,324 | $0.00 | $3.7K | 3.89M | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 162,013 | — | — | 2.76M | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 266,280 | $3.02 | $804.2K | 502.8K | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 266,280 | $3.02 | $804.2K | 0 | Form 4 ↗ |
Redmile Group, LLC
| Apr 20, 2026 | J-Other | 8,977,624 | — | — | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Fate Therapeutics, Inc. (FATE) is primarily owned by institutional investors, who hold approximately 69.2% of total shares outstanding. Company insiders own approximately 12.61%, while retail and public investors account for the remaining 18.23%.
The largest institutional shareholder of Fate Therapeutics, Inc. is REDMILE GROUP, LLC, holding approximately 12.87 million shares — equal to 10.86% of outstanding shares — as of September 30, 2025.
A total of 145 institutional investors currently hold FATE stock, with a combined institutional value of approximately $101,611,264 as of the most recent 13F filing period.
Frequently asked questions
FATE ownershipFate Therapeutics, Inc. (FATE) is primarily owned by institutional investors, who hold approximately 69.2% of shares. The largest shareholder is REDMILE GROUP, LLC with a 10.86% stake. Company insiders hold 12.61%. Data sourced from SEC Form 13F as of September 30, 2025.